FITC Mouse Anti-Human CD7 Antibody (S-575-58)
FITC Mouse Anti-Human CD7 Antibody (S-575-58)
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD7 |
| Synonyms | T-cell antigen CD7; GP40; T-cell leukemia antigen; T-cell surface antigen Leu-9; TP41 |
| Immunogen | Recombinant Protein |
| Location | Membrane |
| Accession | P09564 |
| Clone Number | S-575-58 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Hu |
| Purification | Protein G |
| Conjugation | FITC |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5 μl per million cells in 100μl volume |
Background
CD7, also known as GP40, is a transmembrane glycoprotein and a member of the immunoglobulin superfamily, primarily expressed on the surface of T cells and natural killer (NK) cells. It is highly expressed in acute T-cell leukemia (T-ALL) and certain peripheral T-cell lymphomas. CD7 plays a significant role in the regulation and activation of the immune system. It is involved in T-cell and T-cell/B-cell interactions during early lymphoid development and acts as a co-stimulatory molecule with CD3, CD45, and PI3K. CD7 has two known ligands, K12 protein and galectin-1, which can influence T cell proliferation, migration, and apoptosis. Additionally, CD7 is being explored as a target for cancer therapies, such as antibody-drug conjugates, due to its high expression in certain malignancies.
